Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Hydrocortisone Acetate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 known ✓ | P04150 | 5/20 | 0.78 |
| ▸ | HIF1A | Q16665 | 11/20 | 1.00 |
| ▸ | PGR | P06401 | 4/20 | 1.00 |
| ▸ | AR | P10275 | 3/20 | 1.00 |
| ▸ | SERPINA6 | P08185 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 2/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.81 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.80 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.78 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.78 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.78 |
| ▸ | MAPT | P10636 | 2/20 | 0.78 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.78 |
| ▸ | SHBG | P04278 | 1/20 | 0.78 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.78 |
| ▸ | TSHR | P16473 | 2/20 | 0.77 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.77 |
| ▸ | POLB | P06746 | 1/20 | 0.76 |
| ▸ | GAA | P10253 | 1/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrocortisone Acetate SCHEMBL2679809 | 1.00 | HIF1A (1.00) | HIF1APGRARSERPINA6LMNA | |
| Hydrocortisone Acetate SCHEMBL25599370 | 1.00 | HIF1A (1.00) | HIF1APGRARSERPINA6LMNA | |
| Hydrocortisone Acetate SCHEMBL7419 | 1.00 | HIF1A (1.00) | HIF1APGRARSERPINA6LMNA | |
| Hydrocortisone Acetate SCHEMBL2452043 | 1.00 | HIF1A (1.00) | HIF1APGRARSERPINA6LMNA | |
| Hydrocortisone Acetate SCHEMBL13026148 | 1.00 | HIF1A (1.00) | HIF1APGRARSERPINA6LMNA | |
| Hydrocortisone Acetate SCHEMBL11238411 | 0.99 | HIF1A (0.98) | HIF1APGRARSERPINA6LMNA | |
| Hydrocortisone Acetate SCHEMBL11238414 | 0.99 | HIF1A (0.98) | HIF1APGRARSERPINA6LMNA | |
| Hydrocortisone Acetate SCHEMBL2832039 | 0.99 | HIF1A (0.98) | HIF1APGRARSERPINA6LMNA | |
| Hydrocortisone Acetate SCHEMBL365254 | 0.97 | HIF1A (0.93) | HIF1APGRARSERPINA6LMNA | |
| Hydrocortisone Acetate SCHEMBL7520412 | 0.97 | HIF1A (0.93) | HIF1APGRARSERPINA6LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180235882-A1 | TOPICAL COMPOSITIONS COMPRISING CORTICOSTEROIDS | CADILA HEALTHCARE LIMITED (IN) | 2018-08-23 | — | — | US | claimed |
| US-5426198-A | Contacting steroid in solution with chromium ion, hydrogen radical source, reducing agent | THE UPJOHN COMPANY (US) | 1995-06-20 | — | — | US | claimed |
| EP-0374185-B1 | IMPROVED 9$g(a)-DEHALOGENATION PROCESS | THE UPJOHN COMPANY (US) | 1993-02-10 | — | — | EP | claimed |
| EP-0374185-A1 | IMPROVED 9-g(a)-DEHALOGENATION PROCESS. | UPJOHN CO (US) | 1990-06-27 | — | — | EP | claimed |
| WO-1989001482-A1 | IMPROVED 9alpha-DEHALOGENATION PROCESS | THE UPJOHN COMPANY (US) | 1989-02-23 | — | — | WO | claimed |
| US-4749649-A | Microbial Δ1-dehydrogenation process using a scavenger of toxic oxygen | THE UPJOHN COMPANY (US) | 1988-06-07 | — | — | US | claimed |
| EP-0127294-B1 | STEROID DEHYDROGENATION | THE UPJOHN COMPANY (US) | 1986-12-17 | — | — | EP | claimed |
| EP-0127294-A1 | Steroid dehydrogenation | THE UPJOHN COMPANY (US) | 1984-12-05 | — | — | EP | claimed |
| US-20180235882-A1 | TOPICAL COMPOSITIONS COMPRISING CORTICOSTEROIDS | CADILA HEALTHCARE LIMITED (IN) | 2018-08-23 | — | — | US | disclosed |
| US-20080139545-A1 | FORMULATION TO TREAT EAR INFECTION | CHOE WON-TAEK | 2008-06-12 | — | — | US | disclosed |
| US-20060134226-A1 | Compositions useful to treat ocular neovascular diseases and macular degeneration | NU-TEIN CO., LTD. | 2006-06-22 | — | — | US | disclosed |
| US-20060122282-A1 | METHOD FOR TREATING SKIN DISORDERS WITH XANTHOPHYLLS | NU-TEIN CO., INC. | 2006-06-08 | — | — | US | disclosed |
| US-20050089473-A1 | Potassium channel mediated delivery of agents through the blood-brain barrier | CEDARS-SINAI MEDICAL CENTER | 2005-04-28 | — | — | US | disclosed |
| US-20020042394-A1 | Cobalamin compounds useful as antibiotic agents and as imaging agents | HOGENKAMP HENRICUS P C (US) | 2002-04-11 | — | — | US | disclosed |
| US-4568492-A | HYDROSILYLATION THEN PERACID OXIDATION | THE UPJOHN COMPANY (US) | 1986-02-04 | — | — | US | disclosed |
| EP-0127294-A1 | Steroid dehydrogenation | THE UPJOHN COMPANY (US) | 1984-12-05 | — | — | EP | disclosed |
| US-4305936-A | SOLUBILIZERS CONSISTING OF FATTY ACID GLYCERIDES, COCAMIDOPROPYL BETAINE AND A GLYCOL | DERMIK LABORATORIES (US) | 1981-12-15 | — | — | US | disclosed |
| US-4154748-A | Phosphate catalyzed acylation of steroidal tertiary alcohols | THE UPJOHN COMPANY (US) | 1979-05-15 | — | — | US | disclosed |
| US-4083974-A | Topical steroidal anti-inflammatory preparations containing polyoxypropylene 15 stearyl ether | THE UPJOHN COMPANY (US) | 1978-04-11 | — | — | US | disclosed |
| US-4017615-A | ESPECIALLY USEFUL FOR ANTIINFLAMMATORY TOPICAL CORTICOIDS | SYNTEX CORPORATION (PM) | 1977-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060134226-A1 | Compositions useful to treat ocular neovascular diseases and macular degeneration | CFD, VEGFA, CFH | NR3C1 1801/4885HIF1A 931/4885PGR 610/4885 |
| US-20050089473-A1 | Potassium channel mediated delivery of agents through the blood-brain barrier | KCNN2, KCNN1, KCNN3 | NR3C1 3349/4885HIF1A 387/4885PGR 1349/4885 |
| US-20020042394-A1 | Cobalamin compounds useful as antibiotic agents and as imaging agents | MMAB, BLVRB, AHCY | NR3C1 4858/4885HIF1A 2552/4885PGR 3179/4885 |
| US-20060122282-A1 | METHOD FOR TREATING SKIN DISORDERS WITH XANTHOPHYLLS | COL1A1, COL2A1, KRT18 | NR3C1 3140/4885HIF1A 923/4885PGR 29/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.